Literature DB >> 16543148

Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.

Bhushan Nagar1, Oliver Hantschel, Markus Seeliger, Jason M Davies, William I Weis, Giulio Superti-Furga, John Kuriyan.   

Abstract

The tyrosine kinase c-Abl is inactivated by interactions made by its SH3 and SH2 domains with the distal surface of the kinase domain. We present a crystal structure of a fragment of c-Abl which reveals that a critical N-terminal cap segment, not visualized in previous structures, buttresses the SH3-SH2 substructure in the autoinhibited state and locks it onto the distal surface of the kinase domain. Surprisingly, the N-terminal cap is phosphorylated on a serine residue that interacts with the connector between the SH3 and SH2 domains. Small-angle X-ray scattering (SAXS) analysis shows that a mutated form of c-Abl, in which the N-terminal cap and two other key contacts in the autoinhibited state are deleted, exists in an extended array of the SH3, SH2, and kinase domains. This alternative conformation of Abl is likely to prolong the active state of the kinase by preventing it from returning to the autoinhibited state.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16543148     DOI: 10.1016/j.molcel.2006.01.035

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  97 in total

1.  Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance.

Authors:  Oliver Hantschel
Journal:  Haematologica       Date:  2012-02       Impact factor: 9.941

2.  Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.

Authors:  Teodora Pene-Dumitrescu; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

3.  Roles of the SH2 and SH3 domains in the regulation of neuronal Src kinase functions.

Authors:  Bradley R Groveman; Sheng Xue; Vedrana Marin; Jindong Xu; Mohammad K Ali; Ewa A Bienkiewicz; Xian-Min Yu
Journal:  FEBS J       Date:  2010-12-30       Impact factor: 5.542

Review 4.  Treatment for chronic myelogenous leukemia: the long road to imatinib.

Authors:  Tony Hunter
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

5.  Two kinase family dramas.

Authors:  Thomas A Leonard; James H Hurley
Journal:  Cell       Date:  2007-06-15       Impact factor: 41.582

6.  Dynamically Coupled Residues within the SH2 Domain of FYN Are Key to Unlocking Its Activity.

Authors:  Radu Huculeci; Elisa Cilia; Agatha Lyczek; Lieven Buts; Klaartje Houben; Markus A Seeliger; Nico van Nuland; Tom Lenaerts
Journal:  Structure       Date:  2016-09-29       Impact factor: 5.006

7.  Conformational snapshots of Tec kinases during signaling.

Authors:  Raji E Joseph; Amy H Andreotti
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

8.  Structure, regulation, signaling, and targeting of abl kinases in cancer.

Authors:  Oliver Hantschel
Journal:  Genes Cancer       Date:  2012-05

9.  Crk and ABI1: binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton.

Authors:  Sajjad Hossain; Patrycja M Dubielecka; Aleksander F Sikorski; Raymond B Birge; Leszek Kotula
Journal:  Genes Cancer       Date:  2012-05

10.  Abl N-terminal cap stabilization of SH3 domain dynamics.

Authors:  Shugui Chen; Teodora Pene Dumitrescu; Thomas E Smithgall; John R Engen
Journal:  Biochemistry       Date:  2008-05-02       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.